Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 7/20 | 0.68 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.68 |
| ▸ | EP300 | Q09472 | 5/20 | 0.68 |
| ▸ | FSCN1 | Q16658 | 4/20 | 0.68 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | BLM | P54132 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | TDP2 | O95551 | 1/20 | 0.59 |
| ▸ | NSD2 | O96028 | 1/20 | 0.59 |
| ▸ | BCL2 | P10415 | 1/20 | 0.59 |
| ▸ | CFTR | P13569 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.59 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.59 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.59 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937504 | 1.00 | KEAP1 (0.68) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL15521861 | 1.00 | KEAP1 (0.68) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510145 | 0.92 | KEAP1 (0.66) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510270 | 0.90 | MCL1 (0.61) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510146 | 0.90 | KEAP1 (0.59) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510149 | 0.90 | HKDC1 (0.68) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510268 | 0.89 | MCL1 (0.64) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510271 | 0.88 | KEAP1 (0.54) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL13510230 | 0.88 | BRAF (0.70) | KEAP1NFE2L2EP300FSCN1MCL1 | |
| SCHEMBL15521814 | 0.88 | KEAP1 (0.70) | KEAP1NFE2L2EP300FSCN1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368657-A1 | METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12384791-B2 | Methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240158402-A1 | METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11866440-B2 | Methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158402-A1 | METHODS FOR INHIBITING FASCIN | FSCN1, NLN, TNNI3 | KEAP1 1911/4885NFE2L2 2091/4885EP300 2330/4885 |
| US-12384791-B2 | Methods for inhibiting fascin | FSCN1, NLN, TNNI3 | KEAP1 1911/4885NFE2L2 2091/4885EP300 2330/4885 |
| US-20250368657-A1 | METHODS FOR INHIBITING FASCIN | FSCN1, NLN, TNNI3 | KEAP1 1911/4885NFE2L2 2091/4885EP300 2330/4885 |
| US-11866440-B2 | Methods for inhibiting fascin | FSCN1, NLN, TNNI3 | KEAP1 1911/4885NFE2L2 2091/4885EP300 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.